Support Line: 0300 373 8500
This is a first-in-human study, meaning that the drug has not been tested on humans before. Researchers are testing to find the best dose, safety and efficacy of NX-5948 or Bexobrutideg, which is a new type of drug called a BTK degrader. This type of drug targets proteins called BTK that help cancer cells to grow and has recently been designated Orphan Status by the FDA, meaning there is more funding available to develop it in a rare patient population..
Because Bexobrutideg is in the early phases of trials, not much is known about it and researchers don’t know who will benefit from it. However, findings from the trial will inform future studies and trials, meaning it will help people with WM in the future.
• A confirmed diagnosis of WM
• WM that has returned or not responded to prior treatment
• You must have had at least two prior lines of treatment and have no further treatment options available
